Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INZY Inozyme Pharma

Pre-Market Trading 11-15 06:59:10 EST

3.43

-0.12

-3.38%

High3.60	Low3.41	Vol321.04K
Open3.59	D1 Closing3.55	Amplitude5.21%
Mkt Cap220.34M	Tradable Cap135.08M	Total Shares64.24M
T/O1.12M	T/O Rate0.82%	Tradable Shares39.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"INZY","market":"US","secType":"STK","nameCN":"Inozyme Pharma","latestPrice":3.43,"timestamp":1731618000000,"preClose":3.55,"halted":0,"volume":321042,"delay":0,"floatShares":39380500,"shares":64240198,"eps":-1.550867,"marketStatus":"Pre-Market Trading","change":-0.12,"latestTime":"11-15 06:59:10 EST","open":3.59,"high":3.595,"low":3.41,"amount":1120245.8019,"amplitude":0.052113,"askPrice":5.48,"askSize":200,"bidPrice":3.11,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.550867,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1731681000000},"marketStatusCode":1,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":3.43,"postHourTrading":{"tag":"盘后","latestPrice":3.6,"preClose":3.43,"latestTime":"18:56 EST","volume":11589,"amount":39803.6101,"timestamp":1731628587855},"volumeRatio":0.9877043787616538,"impliedVol":3.7998,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/INZY","defaultTab":"news","newsList":[{"id":"2483688836","title":"Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2483688836","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483688836?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:35","pubTimestamp":1731508506,"startTime":"0","endTime":"0","summary":"A downtrend has been apparent in Inozyme Pharma, Inc.  lately with too much selling pressure. The stock has declined 30% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.However, like every investing tool, RSI has its lim","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-inozyme-pharma-inzy-143506800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RSI","BK4139","BK4150","INZY"],"gpt_icon":0},{"id":"2482239781","title":"Inozyme Pharma to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2482239781","media":"GlobeNewswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482239781?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:30","pubTimestamp":1731331800,"startTime":"0","endTime":"0","summary":"BOSTON, Nov.  11, 2024  (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare dis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978304/0/en/Inozyme-Pharma-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2481189671","title":"Inozyme Pharma Receives Buy Rating for Promising Pipeline and Strategic Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2481189671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481189671?lang=en_us&edition=fundamental","pubTime":"2024-11-06 19:16","pubTimestamp":1730891773,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Edward White has reiterated their bullish stance on INZY stock, giving a Buy rating yesterday. Edward White has given his B...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/inozyme-pharma-receives-buy-rating-for-promising-pipeline-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/inozyme-pharma-receives-buy-rating-for-promising-pipeline-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INZY"],"gpt_icon":0},{"id":"2481813620","title":"Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2481813620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481813620?lang=en_us&edition=fundamental","pubTime":"2024-11-06 17:52","pubTimestamp":1730886720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INZY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2024 04:52 ET (09:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2481641921","title":"U.S. RESEARCH ROUNDUP-Apollo, Booking Holdings, Portillos","url":"https://stock-news.laohu8.com/highlight/detail?id=2481641921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481641921?lang=en_us&edition=fundamental","pubTime":"2024-11-06 15:01","pubTimestamp":1730876499,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apollo, Booking Holdings and Portillos, on Wednesday.    HIGHLIGHT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","AGCO","MYE","BK4184","ARIS","CART","BVS","APLS","LDOS","IE0034235188.USD","FRPT","IT","LU0154245756.USD","AHCO","ANAB","LU0154245673.USD","EXAS","LU0225283273.USD","MASI","FIS","GXO","ABNB","MTH","AZPN","INZY","HPK","LIND","CE","CMI","PAYO","JELD","LTC","BKNG","APO","GMED","CTRE","BR","MPLN","AIG","IE0002270589.USD","BRKR","BK4554","LU0203347892.USD","CHH","OHI","LUMN","PTLO","ACLX","MCHP"],"gpt_icon":1},{"id":"2481494648","title":"Inozyme Pharma Inc :  Jefferies Cuts Target Price to $15 From $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2481494648","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481494648?lang=en_us&edition=fundamental","pubTime":"2024-11-06 13:59","pubTimestamp":1730872767,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nFWN3MD01V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2481612896","title":"Inozyme Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481612896","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481612896?lang=en_us&edition=fundamental","pubTime":"2024-11-06 12:58","pubTimestamp":1730869085,"startTime":"0","endTime":"0","summary":"* Inozyme Pharma Inc    reported a quarterly adjusted loss of 39 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -29 cents. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Inozyme Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2481151611","title":"Inozyme Pharma’s Q3 2024 Financial and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2481151611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481151611?lang=en_us&edition=fundamental","pubTime":"2024-11-06 12:34","pubTimestamp":1730867659,"startTime":"0","endTime":"0","summary":"Inozyme Pharma, Inc. ( ($INZY) ) has released its Q3 earnings. Here is a breakdown of the information Inozyme Pharma, Inc. presented to its investo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inozyme-pharmas-q3-2024-financial-and-clinical-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inozyme-pharmas-q3-2024-financial-and-clinical-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4097","LU2065732104.USD","INZY","PRGS"],"gpt_icon":0},{"id":"2481587776","title":"Inozyme Pharma’s Strategic and Financial Positioning Bolsters Buy Rating Amid Upcoming Trial Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2481587776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481587776?lang=en_us&edition=fundamental","pubTime":"2024-11-06 04:15","pubTimestamp":1730837734,"startTime":"0","endTime":"0","summary":"Needham analyst Joseph Stringer has maintained their bullish stance on INZY stock, giving a Buy rating today. Joseph Stringer has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/inozyme-pharmas-strategic-and-financial-positioning-bolsters-buy-rating-amid-upcoming-trial-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/inozyme-pharmas-strategic-and-financial-positioning-bolsters-buy-rating-amid-upcoming-trial-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INZY"],"gpt_icon":0},{"id":"2481637402","title":"Promising Developments in Inozyme Pharma’s INZ-701 Drive Buy Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2481637402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481637402?lang=en_us&edition=fundamental","pubTime":"2024-11-06 03:15","pubTimestamp":1730834128,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm has maintained their bullish stance on INZY stock, giving a Buy rating on October 25. Marc Frahm has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-in-inozyme-pharmas-inz-701-drive-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-in-inozyme-pharmas-inz-701-drive-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2481684711","title":"Wedbush Adjusts Price Target on Inozyme Pharma to $12 From $15, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2481684711","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481684711?lang=en_us&edition=fundamental","pubTime":"2024-11-06 00:15","pubTimestamp":1730823306,"startTime":"0","endTime":"0","summary":"Price: 4.33, Change: -0.09, Percent Change: -2.04","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INZY"],"gpt_icon":0},{"id":"2481686378","title":"Inozyme Pharma Inc : Wedbush Cuts Target Price to $12 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2481686378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481686378?lang=en_us&edition=fundamental","pubTime":"2024-11-05 23:18","pubTimestamp":1730819913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC1UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INZY"],"gpt_icon":0},{"id":"2481491501","title":"Inozyme Pharma Q3 EPS $(0.39) Beats $(0.44) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481491501","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481491501?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:38","pubTimestamp":1730813933,"startTime":"0","endTime":"0","summary":"Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.44) by 11.36 percent. This is a 34.48 percent decrease over losses of $(0.29) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41744440/inozyme-pharma-q3-eps-0-39-beats-0-44-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Inozyme Pharma Q3 EPS $(0.39) Beats $(0.44) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0},{"id":"2481501351","title":"Inozyme Pharma Inc:  Interim Data From Energy 1, a Phase 1B Trial of Inz-701 in Infants With Enpp1 Deficiency, on Track for Q4 of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481501351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481501351?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA8BCNC0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2481399501","title":"Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481399501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481399501?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA8BCNC0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2481013665","title":"Inozyme Pharma: Cash, Cash Equivalents, and Short-Term Investments as of September 30, 2024, Expected to Fund Operations Into Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481013665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481013665?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA8BCNC0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2481090185","title":"Inozyme Pharma Q3 Net Income USD -24.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481090185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481090185?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nPLX569AE2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INZY","BK4139"],"gpt_icon":0},{"id":"2481950195","title":"Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481950195","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481950195?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:30","pubTimestamp":1730813400,"startTime":"0","endTime":"0","summary":"- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –。- Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 -. - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding -. BOSTON, Nov. 05, 2024  -- Inozyme Pharma, Inc. , a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.Phase 1 Trial of INZ-701 in Patients with End-Stage Kidney Disease  Undergoing Hemodialysis. In October 2024, the Company announced positi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TtfUSRcXuiiTrUF2RvpvvQ--~B/aD0yNTI7dz05MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3bb9ff2ad714f6f291f9fd0b6a76f48b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TtfUSRcXuiiTrUF2RvpvvQ--~B/aD0yNTI7dz05MTE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3bb9ff2ad714f6f291f9fd0b6a76f48b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inozyme-pharma-reports-third-quarter-133000375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","INZY","PXE"],"gpt_icon":0},{"id":"2481761145","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2481761145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481761145?lang=en_us&edition=fundamental","pubTime":"2024-11-05 19:00","pubTimestamp":1730804400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·AG Mtge Invest.                                 3Q       .21    6:30 AM. ·American Fncl Gp                                 3Q      2.47    5:00 PM. ·Apollo Global Mgmnt                              3Q      1.73    6:30 AM. ·Bain Cap Spec Fin                               3Q       .50        AMC. ·Ballard Power Sys                               3Q      (.13)   8:30 AM. ·Broadridge Fncl Sltns                             1Q       .97    7:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTKB","INNV","FTS","CTLT","MGNX","OGE","AGEN","BLDP","FORR","LPX","MRCY","CGBD","EVRI","CRC","MITT","HSIC","GGB","BBAI","NMRK","JKHY","MLYS","AIP","SWIM","RNA","DD","GBTG","ERO","EXK","GMED","BLDR","MRNS","AFG","LUMN","INZY","OLMA","ARCH","AGCO","GLDD","CRBP","NVEI","APO","MRC","CMI","FHTX","IMOS","LDI","RACE","BRKR","NOG"],"gpt_icon":1},{"id":"2480805798","title":"Inozyme Pharma Inc    expected to post a loss of 44 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480805798","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480805798?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:52","pubTimestamp":1730472756,"startTime":"0","endTime":"0","summary":"* Inozyme Pharma Inc     is expected to show no change in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2024   *    * LSEG's mean analyst esti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Inozyme Pharma Inc    expected to post a loss of 44 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INZY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inozyme.com","stockEarnings":[{"period":"1week","weight":-0.1634},{"period":"1month","weight":-0.3613},{"period":"3month","weight":-0.2511},{"period":"6month","weight":-0.2543},{"period":"1year","weight":0.0719},{"period":"ytd","weight":-0.1948}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.398674},{"month":2,"riseRate":0.5,"avgChangeRate":0.035032},{"month":3,"riseRate":0.5,"avgChangeRate":0.231994},{"month":4,"riseRate":0,"avgChangeRate":-0.140893},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000114},{"month":6,"riseRate":0.5,"avgChangeRate":0.047361},{"month":7,"riseRate":0.25,"avgChangeRate":-0.006548},{"month":8,"riseRate":0.2,"avgChangeRate":0.036393},{"month":9,"riseRate":0,"avgChangeRate":-0.135388},{"month":10,"riseRate":0,"avgChangeRate":-0.227258},{"month":11,"riseRate":0.4,"avgChangeRate":-0.019483},{"month":12,"riseRate":0.25,"avgChangeRate":-0.129297}],"exchange":"NASDAQ","name":"Inozyme Pharma","nameEN":"Inozyme Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inozyme Pharma(INZY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inozyme Pharma,INZY,Inozyme Pharma股票,Inozyme Pharma股票老虎,Inozyme Pharma股票老虎国际,Inozyme Pharma行情,Inozyme Pharma股票行情,Inozyme Pharma股价,Inozyme Pharma股市,Inozyme Pharma股票价格,Inozyme Pharma股票交易,Inozyme Pharma股票购买,Inozyme Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inozyme Pharma(INZY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inozyme Pharma(INZY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction